Human Patents (Class 530/388.15)
  • Patent number: 10369155
    Abstract: The present invention provides a method for treating or alleviating a symptom of a disorder, e.g., immune evasion, cancer-cell induced immune dysfunction, reduced immune response, lowered inflammation, decreased expression of a major histocompatibility complex (MHC), or cancer, characterized by aberrant, misregulated, or increased Enhancer of Zeste Homolog 2 (EZH2) activity in a cell or subject in need thereof by contacting the cell or administering to the subject a therapeutically effective amount of an EZH2 inhibitor.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: August 6, 2019
    Assignee: Epizyme, Inc.
    Inventor: Heike Keilhack
  • Patent number: 10350261
    Abstract: Hyper-inflammatory responses can lead to a variety of diseases including sepsis. It is now shown that extracellular histones released in response to inflammatory challenge are mediators contributing to endothelial dysfunction, organ failure and death during sepsis. As such, they can be targeted pharmacologically by inhibitors, as well as used as biomarkers for prognosis of sepsis and other diseases.
    Type: Grant
    Filed: June 9, 2015
    Date of Patent: July 16, 2019
    Assignee: OKLAHOMA MEDICAL RESEARCH FOUNDATION
    Inventors: Charles T. Esmon, Jun Xu, Xiaomei Zhang
  • Patent number: 10238711
    Abstract: Hyper-inflammatory responses can lead to a variety of diseases including sepsis. It is now shown that extracellular histones released in response to inflammatory challenge are mediators contributing to endothelial dysfunction, organ failure and death during sepsis. As such, they can be targeted pharmacologically by inhibitors, as well as used as biomarkers for prognosis of sepsis and other diseases.
    Type: Grant
    Filed: May 6, 2014
    Date of Patent: March 26, 2019
    Assignee: OKLAHOMA MEDICAL RESEARCH FOUNDATION
    Inventors: Charles T. Esmon, Jun Xu, Xiaomei Zhang
  • Patent number: 10239938
    Abstract: The present invention concerns compositions and methods of use of T-cell redirecting complexes, with at least one binding site for a T-cell antigen and at least one binding site for an antigen on a diseased cell or pathogen. Preferably, the complex is a DNL™ complex. More preferably, the complex comprises a bispecific antibody (bsAb). Most preferably, the bsAb is an anti-CD3×anti-CD19 bispecific antibody, although antibodies against other T-cell antigens and/or disease-associated antigens may be used. The complex is capable of targeting effector T cells to induce T-cell-mediated cytotoxicity of cells associated with a disease, such as cancer, autoimmune disease or infectious disease. The cytotoxic immune response is enhanced by co-administration of interferon-based agents that comprise interferon-?, interferon-?, interferon-?1, interferon-?2 or interferon-?3.
    Type: Grant
    Filed: October 10, 2016
    Date of Patent: March 26, 2019
    Assignee: IBC Pharmaceuticals, Inc.
    Inventors: Chien-Hsing Chang, David M. Goldenberg, Edmund A. Rossi, Diane Rossi, Hans J. Hansen
  • Patent number: 10202454
    Abstract: The present invention is based, in part, on the discovery of monoclonal antibodies that specifically bind to the cytoplasmic domain of PD-L1 antibodies useful for diagnostic, prognostic, and therapeutic applications, as well as immunoglobulins polypeptides, and nucleic acids thereof.
    Type: Grant
    Filed: October 24, 2014
    Date of Patent: February 12, 2019
    Assignees: Dana-Farber Cancer Institute, Inc., President and Fellows of Harvard College
    Inventors: Gordon J. Freeman, Arlene H. Sharpe
  • Patent number: 10189909
    Abstract: The invention relates to antibodies to MASP-2 and functional equivalents thereof. In particular, the invention relates to MASP-2 antibodies capable of inhibiting the function of MASP-2. The invention furthermore discloses MASP-2 epitopes, wherein antibodies recognizing said epitopes are in particularly useful for inhibiting MASP-2 activity. The invention also relates to methods of producing said antibodies, methods of inhibiting MASP-2 activity as well as to pharmaceutical compositions comprising the MASP-2 antibodies.
    Type: Grant
    Filed: June 19, 2015
    Date of Patent: January 29, 2019
    Assignee: Helion Biotech ApS
    Inventors: Flemming Larsen, Ulla Wahlers
  • Patent number: 10160806
    Abstract: The present invention is directed to bi-specific diabodies that comprise two or more polypeptide chains and which possess at least one Epitope-Binding Site that is immunospecific for an epitope of PD-1 and at least one Epitope-Binding Site that is immunospecific for an epitope of LAG-3 (i.e., a “PD-I×LAG-3 bi-specific diabody”). More preferably, the present invention is directed to bi-specific diabodies that comprise four polypeptide chains and which possess two Epitope-Binding Sites that are immunospecific for one (or two) epitope(s) of PD-1 and two Epitope-Binding Site that are immunospecific for one (or two) epitope(s) of LAG-3 (i.e., a “PD-1×LAG-3 bi-specific, tetra-valent diabody”).
    Type: Grant
    Filed: June 19, 2015
    Date of Patent: December 25, 2018
    Assignee: MacroGenics, Inc.
    Inventors: Ezio Bonvini, Leslie S. Johnson, Kalpana Shah, Ross La Motte-Mohs, Paul A. Moore, Scott Koenig
  • Patent number: 9902936
    Abstract: The present invention relates to novel antibody compositions for regulating an immune response in a subject. More particularly, the invention relates to specific antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects. The invention also relates to fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly in therapy, to increase NK cell activity or cytotoxicity in subjects.
    Type: Grant
    Filed: July 1, 2004
    Date of Patent: February 27, 2018
    Assignee: INNATE PHARMA S.A.
    Inventors: Alessandro Moretta, Mariella Della Chiesa
  • Patent number: 9844593
    Abstract: Compositions comprising compounds that neutralize NK cell inhibitory receptors and methods of using such compositions in the treatment of hematological malignancies are provided.
    Type: Grant
    Filed: November 22, 2011
    Date of Patent: December 19, 2017
    Assignee: INNATE PHARMA SA
    Inventors: Pascale Andre, Renaud Buffet, Marcel Rozencweig, Jerome Tiollier
  • Patent number: 9790268
    Abstract: Provided are binding polypeptides (e.g., antibodies), and drug conjugates thereof, comprising an Fc domain with an altered glycosylation profile and reduced effector function. In particular embodiment, the Fc domain comprises: an asparagine residue at amino acid position 298, according to EU numbering; and a serine threonine residue at amino acid position 300, according to EU numbering. Also provided are nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: October 17, 2017
    Assignee: GENZYME CORPORATION
    Inventors: Clark Pan, Huawei Qiu
  • Patent number: 9765147
    Abstract: Methods of treating cancer with antibodies that bind colony stimulating factor 1 receptor (CSF1R) in combination with PD-1/PD-L1 inhibitors are provided.
    Type: Grant
    Filed: October 28, 2015
    Date of Patent: September 19, 2017
    Assignees: Five Prime Therapeutics, Inc., Bristol-Myers Squibb Company
    Inventors: Brian Wong, Julie Hambleton, Robert Sikorski, Emma Masteller, Kevin Hestir, David Bellovin, Katherine E. Lewis
  • Patent number: 9574008
    Abstract: The present invention relates to CD27L antigen binding proteins, such an antibodies, polynucleotides encoding said CD27l antigen binding proteins, antibody drug conjugate compositions, and methods for diagnosing and treating diseases associated with CD27L expression.
    Type: Grant
    Filed: February 10, 2015
    Date of Patent: February 21, 2017
    Assignee: AMGEN INC.
    Inventors: John M. Delaney, William C. Fanslow, III, Chadwick T. King
  • Patent number: 9505833
    Abstract: Methylglyoxal (MGO)-modified recombinant TNF-alpha antibodies (e.g., Adalimumab) are identified. MGO modification decreases binding between Adalimumab and TNF-alpha. Methods are disclosed for reducing the presence of MOO-modified antibodies in the production of Adalimumab TNF-alpha antibodies.
    Type: Grant
    Filed: November 12, 2013
    Date of Patent: November 29, 2016
    Assignee: AbbVie Inc.
    Inventor: Christopher M. Chumsae
  • Patent number: 9359428
    Abstract: Provided herein are antibodies that specifically bind and neutralize Staphylococcus enterotoxin B. In addition, nucleic acids encoding such antibodies, and cells that express such antibodies are provided. Also provided are methods for treating diseases mediated by, and for neutralizing Staphylococcus enterotoxin B.
    Type: Grant
    Filed: October 15, 2014
    Date of Patent: June 7, 2016
    Assignee: Morphotek, Inc.
    Inventors: Philip M. Sass, Nicholas C. Nicolaides, Luigi Grasso, Marc Berger, Tao Sai
  • Patent number: 9328157
    Abstract: The present disclosure relates to novel vascular endothelial growth factor receptor (VEGFR)-binding polypeptides and methods for using these polypeptides to inhibit biological activities mediated by vascular endothelial growth factors (VEGFs). The present disclosure also provides various improvements relating to single domain binding polypeptides.
    Type: Grant
    Filed: November 4, 2013
    Date of Patent: May 3, 2016
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Yan Chen, Elena Getmanova, Martin C. Wright, Alan S. Harris, Ai Ching Lim, Jochem Gokemeijer, Lin Sun, Michael Wittekind
  • Patent number: 9243057
    Abstract: The present disclosure provides antibodies that specifically bind to botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/C, BoNT/D, BoNT/E, BoNT/F, BoNT/G, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.
    Type: Grant
    Filed: August 31, 2011
    Date of Patent: January 26, 2016
    Assignee: The Regents of the University of California
    Inventors: James D. Marks, Maria Consuelo Garcia Rodriguez
  • Patent number: 9229002
    Abstract: The present invention relates to bacteriophage tail proteins and the derivatives and fragments thereof that are capable of binding endotoxins in the absence of bivalent positive ions, especially Ca2+ or Mg2+. Further, the present invention relates to methods for depleting endotoxins from solutions and samples using the bacteriophage tail proteins according to the present invention and to a detection method for endotoxins.
    Type: Grant
    Filed: July 29, 2014
    Date of Patent: January 5, 2016
    Assignee: Hyglos Invest GmbH
    Inventors: Stefan Miller, Roman Meyer, Renate Grassl, Manfred Biebl, Holger Grallert
  • Patent number: 9206255
    Abstract: The invention relates to targeted binding agents against DLL4 and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to DLL4. The described targeted binding agents are useful in the treatment of diseases associated with the activity and/or overproduction of DLL4 and as diagnostics.
    Type: Grant
    Filed: January 30, 2014
    Date of Patent: December 8, 2015
    Assignee: MEDIMMUNE, LLC
    Inventors: Ian Foltz, David Jenkins, Vahe Bedian
  • Patent number: 9109034
    Abstract: The invention relates to human targets of interest (TOI), anti-TOI ligands, kits compositions and method.
    Type: Grant
    Filed: March 17, 2015
    Date of Patent: August 18, 2015
    Assignee: Kymab Limited
    Inventor: Jasper Rupert Clube
  • Patent number: 9067998
    Abstract: The invention relates to human targets of interest (TOI), anti-TOI ligands, kits compositions and method.
    Type: Grant
    Filed: November 10, 2014
    Date of Patent: June 30, 2015
    Assignee: Kymab Limited
    Inventor: Jasper Rupert Clube
  • Patent number: 9051374
    Abstract: A human antibody or a functional fragment thereof having specific binding ability to CD98 which is derived from the cell membrane of cancer cells and is in the form of a complex with a protein having an amino acid transporter activity (for example, LAT1) is disclosed. This antibody binds to CD98 in the form of a dimer with LAT1 on the surface of cancer cells, specifically attacks cancer cells expressing CD98 via the immune system by ADCC or CDC, and further inhibits amino acid uptake of the cancer cells via LAT1, to suppress growth of the cancer cells. Accordingly, a preventive and therapeutic agent for cancer comprising this antibody or a fragment thereof, which acts on various cancers, is specific to cancer, and causes no side effect, is provided.
    Type: Grant
    Filed: July 12, 2013
    Date of Patent: June 9, 2015
    Assignee: KYOWA HAKKO KIRIN CO., LTD
    Inventors: Tomoyuki Tahara, Yoshikatsu Kanai, Hitoshi Endou, Shiro Kataoka, Kazumasa Hasegawa, Tetsuya Yoshino
  • Patent number: 9045545
    Abstract: The invention relates to human targets of interest (TOI), anti-TOI ligands, kits compositions and method.
    Type: Grant
    Filed: November 7, 2014
    Date of Patent: June 2, 2015
    Assignee: Kymab Limited
    Inventor: Jasper Rupert Clube
  • Publication number: 20150141623
    Abstract: The instant invention relates to the field of protein production and purification, and in particular to compositions and processes for controlling the amount of charge variants, aggregates, and fragments of a protein of interest, as well as host cell proteins, present in purified preparations by applying particular chromatography conditions during such protein purification.
    Type: Application
    Filed: December 29, 2014
    Publication date: May 21, 2015
    Inventors: Natarajan RAMASUBRAMANYAN, Lihua YANG, Matthew Omon HERIGSTAD, Hong YANG, Christopher CHUMSAE
  • Publication number: 20150140005
    Abstract: There is provided a method of treating an inflammatory response to infection and complications associated therewith, by administering a proprotein convertase subtilisin kexin 9 (PCSK9) inhibitor to a subject, in need thereof. There is also provided a method of treating or preventing treating or preventing renal failure; renal dysfunction; respiratory failure; respiratory dysfunction; or acute lung injury. Provided herein are uses, pharmaceutical compositions, and commercial packages associated therewith.
    Type: Application
    Filed: May 17, 2013
    Publication date: May 21, 2015
    Inventors: Keith R. Walley, John H. Boyd, James A. Russell
  • Patent number: 9035030
    Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e.g., in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.
    Type: Grant
    Filed: February 21, 2012
    Date of Patent: May 19, 2015
    Assignee: AbbVie Deutschland GmbH & Co. KG
    Inventors: Jochen Salfeld, Michael Roguska, Michael Paskind, Subhashis Banerjee, Daniel Tracey, Michael White, Zehra Kaymakcalan, Boris Labkovsky, Paul Sakorafas, Geertruida M. Veldman, Amy Venturini, Angela Widom, Stuart Friedrich, Nicholas W. Warne, Angela Myles, John Gawain Elvin, Alexander Robert Duncan, Elaine Joy Derbyshire, Sara Carmen, Stephen Smith, Thor Las Holtet, Sarah Leila Du Fou
  • Patent number: 9035026
    Abstract: The present invention relates to binding molecules that specifically bind to the human Fc gamma receptor expressed on the surface of natural killer (NK) cells and macrophages (i.e. Fc?RIIIA), and in particular binding molecules that specifically bind the A form Fc?RIII but do not bind to the B form of Fc?RIII, as well as to the use of such binding molecules in the diagnosis and treatment of disease. The invention further extends to polynucleotides encoding such binding molecules, host cells comprising such polynucleotides and methods of producing binding molecules of the invention using such host cells.
    Type: Grant
    Filed: May 26, 2006
    Date of Patent: May 19, 2015
    Assignee: Affimed GMBH
    Inventors: Karin Hoffmann, Sergey Kipriyanov, Stefan Knackmuss, Fabrice Le Gall, Melvyn Little, Uwe Reusch
  • Publication number: 20150132322
    Abstract: This invention provides a human antibody, a hybridoma cell line for the production of the antibody, a reconstituted mouse strain for the production of the hybridoma, and methods of producing and using thereof.
    Type: Application
    Filed: May 6, 2013
    Publication date: May 14, 2015
    Inventors: Jean Elie Kadouche, Alain Razafindrastita
  • Publication number: 20150132314
    Abstract: This invention provides fully human monoclonal antibodies that recognize IL-17F and/or the heterodimeric IL-17A/IL-17F complex, but do not recognize IL-17A. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and prophylactic.
    Type: Application
    Filed: October 6, 2014
    Publication date: May 14, 2015
    Inventors: Krzysztof MASTERNAK, Francois ROSSEAU
  • Patent number: 9029512
    Abstract: The present invention relates to antibodies that immunospecifically bind to phospho-Akt and certain p-Akt substrates. The invention encompasses human and humanized forms of the antibodies and their use in treating cancers and other proliferative disorders. The invention also relates to p-Akt-derived peptides useful for preparing the antibodies. Methods and compositions for detecting, diagnosing, treating or ameliorating a disease or disorder, especially cancer and other proliferative disorders using the present antibodies also are disclosed.
    Type: Grant
    Filed: November 13, 2009
    Date of Patent: May 12, 2015
    Assignee: Nuclea Biotechnologies, Inc.
    Inventor: Patrick J. Muraca
  • Publication number: 20150125464
    Abstract: The present invention relates to methods of treating immune disorders, particularly autoimmune or inflammatory disorders, and methods of producing antibodies and other compounds for use in therapeutic strategies for treating such disorders. Generally, the present methods involve the use of antibodies or other compounds that prevent the stimulation of NKG2A receptors on NK cells, leading to the lysis of dendritic cells that contribute to the pathology of the disorders.
    Type: Application
    Filed: January 12, 2015
    Publication date: May 7, 2015
    Inventors: ALESSANDRO MORETTA, EMANUELA MARCENARO, FRANCOIS ROMAGNE, PASCALE ANDRE
  • Patent number: 9018357
    Abstract: Anti-VEGF antibodies and variants thereof, including those having high affinity for binding to VEGF, are disclosed. Also provided are methods of using phage display technology with naïve libraries to generate and select the anti-VEGF antibodies with desired binding and other biological activities. Further contemplated are uses of the antibodies in research, diagnostic and therapeutic applications.
    Type: Grant
    Filed: June 25, 2013
    Date of Patent: April 28, 2015
    Assignee: Genentech, Inc.
    Inventors: Germaine Fuh, Hans-Peter Gerber, Wei-Ching Liang, Frederic Fellouse, Sachdev S. Sidhu, Christian Wiesmann
  • Publication number: 20150110776
    Abstract: The invention provides monoclonal antibody 3H6 and related antibodies. The 3H6 antibody binds to an epitope within residues 28-36 of IAPP. The antibodies of the invention are useful, for example, for treating disorders associated with IAPP accumulation, particularly accumulation of IAPP deposits. Such disorders include type 2 diabetes, metabolic syndrome, impaired insulin tolerance, impaired glucose tolerance, insulinomas, and related conditions.
    Type: Application
    Filed: July 11, 2014
    Publication date: April 23, 2015
    Inventors: Robin Barbour, Tarlochan S. Nijjar
  • Publication number: 20150110799
    Abstract: The instant invention relates to low acidic species (AR) compositions comprising a protein, e.g., an antibody, or antigen-binding portion thereof, and methods, e.g., cell culture and/or protein purification methods, for producing such low AR compositions. Methods for using such compositions to treat a disorder, e.g., a disorder in which TNF? is detrimental, are also provided.
    Type: Application
    Filed: November 12, 2013
    Publication date: April 23, 2015
    Inventors: Natarajan RAMASUBRAMANYAN, Lihua YANG, Matthew Omon HERIGSTAD, Hong YANG, Kartik SUBRAMANIAN, Xiaobei ZENG, Diane D. DONG, Wen Chung LIM, Kathreen A. GIFFORD, Zehra KAYMAKCALAN, Christopher CHUMSAE
  • Patent number: 9011858
    Abstract: Novel compositions derived from antigen-binding sites of immunoglobulins having affinity for IL-31 are provided. The compositions exhibit immunological binding properties of antibody molecules capable of binding specifically to a human IL-31. CDR regions derived from same or different immunoglobulin moieties are provided. Also provided are single chain polypeptides wherein VH and VL domains are attached. The sFv molecules can include ancillary polypeptide moieties which can be bioactive, or which provide a site of attachment for other useful moieties. The compositions are useful in specific binding assays, affinity purification schemes, drug or toxin targeting, imaging, and genetic or immunological therapeutics for inflammatory diseases. The invention thus provides novel polypeptides, the DNAs encoding those polypeptides, expression cassettes comprising those DNAs, and methods of inducing the production of the polypeptides.
    Type: Grant
    Filed: May 15, 2013
    Date of Patent: April 21, 2015
    Assignee: ZymoGenetics, Inc.
    Inventors: Anthony W. Siadak, Janine M. Bilsborough, Shirley A. Rene
  • Patent number: 9011856
    Abstract: Compositions and methods relating to antibodies that specifically bind to TGF-beta binding proteins are provided. These methods and compositions relate to altering bone mineral density by interfering with the interaction between a TGF-beta binding protein sclerostin and a TGF-beta superfamily member, particularly a bone morphogenic protein. Increasing bone mineral density has uses in diseases and conditions in which low bone mineral density typifies the condition, such as osteopenia, osteoporosis, and bone fractures.
    Type: Grant
    Filed: November 6, 2012
    Date of Patent: April 21, 2015
    Assignee: UCB Pharma S.A.
    Inventors: David G. Winkler, Jiye Shi, John Latham
  • Publication number: 20150104460
    Abstract: Specific binding members, particularly human antibodies, particularly recombinant antibodies, and fragments thereof, which are capable of binding to and recognizing neurons in the CNS and eliciting responses in CNS neurons are provided. The antibodies are useful in the diagnosis and treatment of conditions associated with nerve damage, injury or degeneration and neurodegenerative disease, and in particular in the treatment or alleviation of stroke or cerebral ischemia. The antibodies, variable regions or CDR domain sequences thereof, and fragments thereof of the invention may also be used in therapy in combination with chemotherapeutics, immune modulators, or neuroactive agents and/or with other antibodies or fragments thereof. The antibodies or active fragments thereof may be used in therapy for stroke or cerebral ischemia alone or in combination with thrombolytics such as TPA. Antibodies are exemplified by the antibodies IgM12 and IgM42 whose sequences are provided herein.
    Type: Application
    Filed: April 17, 2013
    Publication date: April 16, 2015
    Inventors: Moses Rodriguez, Arthur E. Warrington, Larry R. Pease
  • Publication number: 20150099298
    Abstract: The present invention relates to antibodies capable of binding to the coagulation Factor XI and/or its activated form factor XIa and methods of use thereof, particularly methods of use as agents inhibiting platelet aggregation and by this inhibits thrombus formation.
    Type: Application
    Filed: May 8, 2013
    Publication date: April 9, 2015
    Inventors: Andreas Wilmen, Julia Straßburger, Frank Dittmer, Michael Strerath, Anja Buchmüller, Joanna Grudzinska-Goebel, Ricarda Finnern, Martina Schäfer, Christoph Gerdes, Hannah Jörißen, Asako Itakura, Philberta Leung, Erik Tucker
  • Patent number: 9000131
    Abstract: This disclosure provides antibodies that specifically bind to and typically neutralize botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/E, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.
    Type: Grant
    Filed: July 30, 2009
    Date of Patent: April 7, 2015
    Assignee: The Regents of the University of California
    Inventors: James D. Marks, Isin N. Geren
  • Patent number: 8999331
    Abstract: Proteins that bind sclerostin or sclerostin and TNF are described along with there use in composition and methods for treating, preventing, and diagnosing sclerostin related diseases and for detecting sclerostin or sclerostin and TNF in cells, tissues, samples, and compositions.
    Type: Grant
    Filed: October 24, 2012
    Date of Patent: April 7, 2015
    Assignee: AbbVie Inc.
    Inventors: Chung-Ming Hsieh, Alexander Ivanov, Wendy Waegell, Yuliya Kutskova, John Memmott, Lorenzo Benatuil, Jacqueline Bixby, Emma Fung, Sahana Bose, Alyssa Brito
  • Publication number: 20150093800
    Abstract: The present invention provides methods for cleaning or regenerating a chromatography materiel for reuse. The methods of the invention can be used for cleaning or regenerating chromatography columns for reuse in the large-scale manufacture of multiple polypeptide products.
    Type: Application
    Filed: September 5, 2014
    Publication date: April 2, 2015
    Inventors: Ekta MAHAJAN, Kapil KOTHARY, Joanna SO, Jay WERBER
  • Publication number: 20150094455
    Abstract: Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1? and (ii) a constant region that is effective at both activating the complement system though C1q binding and binding to several different Fc receptors.
    Type: Application
    Filed: December 11, 2014
    Publication date: April 2, 2015
    Inventor: John Simard
  • Patent number: 8992916
    Abstract: The present invention relates to human anti-IL-13 binding molecules, particularly antibodies, and to methods for using anti-IL-13 antibody molecules in diagnosis or treatment of IL-13 related disorders, such as asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and Hodgkin's lymphoma.
    Type: Grant
    Filed: October 2, 2013
    Date of Patent: March 31, 2015
    Assignee: Novartis AG
    Inventors: Emma Michelle Campbell, Sofia Parveen, Joe Buechler, Gunars Valkirs
  • Patent number: 8993729
    Abstract: Transgenes encoding exogenous antibodies are stably integrated into donor cells and are present in the somatic tissue of chimeric birds. The transgenes encode exogenous antibodies and are preferably expressed in the oviduct for collection in the egg. Tissue specificity is provided by selecting the content of the transgene accordingly. Birds whose genome is comprised of trangene-derived exogenous antibody-encoding DNA express exogenous antibodies having desirable chemical properties with increased therapeutic utility compared to antibodies derived from bacterial expression systems.
    Type: Grant
    Filed: July 16, 2012
    Date of Patent: March 31, 2015
    Assignee: Synageva Biopharma Corp.
    Inventors: Lei Zhu, Wen Zhou, Robert J. Etches
  • Patent number: 8992908
    Abstract: The present invention is directed to therapeutic methods using IL-6 antagonists such as anti-IL-6 antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat mucositis (e.g., oral mucositis) including persons on a treatment regimen with a drug or chemotherapy and/or radiation for cancer (e.g., head and neck cancer) that is associated with increased risk of mucositis, including oral mucositis.
    Type: Grant
    Filed: November 23, 2011
    Date of Patent: March 31, 2015
    Assignee: Alderbio Holdings LLC
    Inventors: Jeffrey T.L. Smith, Leon F. Garcia-Martinez, Andrew L. Feldhaus
  • Patent number: 8992913
    Abstract: The disclosure provides improved neutralizing anti-GDF-8 antibodies capable of substantially higher levels of expression in host cells compared to previous anti-GDF-8 antibodies. Also provided are methods of using compositions comprising such antibodies to increase muscle mass or strength, and to treat or prevent muscular disorders, neuromuscular disorders, metabolic disorders, adipose tissue disorders or bone disorders.
    Type: Grant
    Filed: June 12, 2013
    Date of Patent: March 31, 2015
    Assignee: Pfizer Inc.
    Inventors: Michelle M. Mader, James R. Apgar, Kevin D. Parris
  • Patent number: 8992911
    Abstract: Compositions and methods relating to antibodies that specifically bind to TGF-beta binding proteins are provided. These methods and compositions relate to altering bone mineral density by interfering with the interaction between a TGF-beta binding protein sclerostin and a TGF-beta superfamily member, particularly a bone morphogenic protein. Increasing bone mineral density has uses in diseases and conditions in which low bone mineral density typifies the condition, such as osteopenia, osteoporosis, and bone fractures.
    Type: Grant
    Filed: November 6, 2012
    Date of Patent: March 31, 2015
    Assignee: UCB Pharma S.A.
    Inventors: David G. Winkler, Jiye Shi, John Latham
  • Patent number: 8992920
    Abstract: The present invention is directed to therapeutic methods using IL-6 antagonists such as anti-IL-6 antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat rheumatoid arthritis.
    Type: Grant
    Filed: November 23, 2011
    Date of Patent: March 31, 2015
    Assignee: Alderbio Holdings LLC
    Inventor: Jeffrey T. L. Smith
  • Patent number: 8987418
    Abstract: Engineered multivalent and multispecific binding proteins that bind IL-1? and/or IL-17 are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease.
    Type: Grant
    Filed: July 3, 2014
    Date of Patent: March 24, 2015
    Assignee: AbbVie Inc.
    Inventors: Tariq Ghayur, JiJie Gu, Maria Harris, Carrie Goodreau, Sonal Saluja
  • Patent number: 8987422
    Abstract: The present invention relates to CD27L antigen binding proteins, such an antibodies, polynucleotides encoding said CD27l antigen binding proteins, antibody drug conjugate compositions, and methods for diagnosing and treating diseases associated with CD27L expression.
    Type: Grant
    Filed: September 20, 2012
    Date of Patent: March 24, 2015
    Assignee: Amgen Inc.
    Inventors: John M. Delaney, William Christian Fanslow, III, Chadwick Terence King
  • Patent number: 8986686
    Abstract: The present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS® or an antigen-binding fragment thereof, even during long periods of storage. In particular, the present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof which immunospecifically binds to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides method of preventing, treating or ameliorating symptoms associated with RSV infection utilizing liquid formulations of the present invention.
    Type: Grant
    Filed: April 30, 2013
    Date of Patent: March 24, 2015
    Assignee: MedImmune, LLC
    Inventors: Cynthia N. Oliver, Erica Shane, Benjamin S. Isaacs, Christian B. Allan, Stephen T. Chang